Autoimmune polyglandular syndromes

Pediatric Endocrinology: Fourth Edition

Volumn , Issue , 2014, Pages

  Haller, Michael J ^a   Winter, William E ^a   Schatz, Desmond A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902420663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4858-7.00029-9     Document Type: Chapter

References (180)

1. Ballotti S., Chiarelli F., de Martino M Autoimmunity. basic mechanisms and implications in endocrine diseases. Part I. Horm Res 2006, 66:132-141.
2. Ballotti S., Chiarelli F., de Martino M Autoimmunity. basic mechanisms and implications in endocrine diseases. Part II. Horm Res 2006, 66:142-152.
3. Anderson M.S, Venanzi E.S, Klein L, et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 2002, 298:1395-1401.
4. Mathis D., Benoist C A decade of AIRE. Nat Rev Immunol 2007, 7:645-650.
5. Cho J.H, Gregersen P.K Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011, 365:1612-1623.
6. Delves P.J, Roitt I.M The immune system. First of two parts. N Engl J Med 2000, 343:37-49.
7. Delves P.J, Roitt I.M The immune system. Second of two parts. N Engl J Med 2000, 343:108-117.
8. Unanue E.R Perspective on antigen processing and presentation. Immunol Rev 2002, 185:86-102.
9. Cresswell P, Ackerman A.L, Giodini A, et al. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005, 207:145-157.
10. Holling T.M, Schooten E., van Den Elsen P.J Function and regulation of MHC class II molecules in T-lymphocytes. of mice and men. Human Immunology 2004, 65:282-290.
11. Neefjes J., Jongsma M.L, Paul P., Bakke O Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011, 11:823-836.
12. Ruan Q.G, Tung K., Eisenman D, et al. The autoimmune regulator directly controls the expression of genes critical for thymic epithelial function. J Immunol 2007, 178:7173-7180.
13. Anderson M.S, Venanzi E.S, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005, 23:227-239.
14. Nagamine K., Peterson P., Scott H.S, et al. Positional cloning of the APECED gene. Nat Genet 1997, 17:393-398.
15. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains The Finnish-German APECED Consortium. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Nat Genet 1997, 17:399-403.
16. Edelmann S.L, Marconi P., Brocker T Peripheral T cells re-enter the thymus and interfere with central tolerance induction. J Immunol 2011, 186:5612-5619.
17. von Boehmer H., Aifantis I., Gounari F, et al. Thymic selection revisited. how essential is it. Immunol Rev 2003, 191:62-78.
18. von Boehmer H., Kisielow P Self-nonself discrimination by T cells. Science 1990, 248:1369-1373.
19. Ramsdell F., Fowlkes B.J Clonal deletion versus clonal anergy. the role of the thymus in inducing self tolerance. Science 1990, 248:1342-1348.
20. Mathis D., Benoist C Back to central tolerance. Immunity 2004, 20:509-516.
21. Abbas A.K, Murphy K.M, Sher A Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
22. O'Shea J.J, Paul W.E Mechanisms underlying lineage commitment and plasticity of helper CD41 T cells. Science 2010, 327:1098-1102.
23. Lan R.Y, Ansari A.A, Lian Z.X, Gershwin M.E Regulatory T cells. development, function and role in autoimmunity. Autoimmun Rev 2005, 4:351-363.
24. Ziegler S.F FOXP3. of mice and men. Annu Rev Immunol 2006, 24:209-226.
25. Kyewski B., Klein L A central role for central tolerance. Annu Rev Immunol 2006, 24:571-606.
26. Fuchizawa T., Adachi Y., Ito Y, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006, 116:1713-1722.
27. Le Bras S., Geha R.S IPEX and the role of Foxp3 in the development and function of human Tregs. J Clin Invest 2006, 116:1473-1475.
28. Meffre E The establishment of early B cell tolerance in humans. lessons from primary immunodeficiency diseases. Ann NY Acad Sci 2012, 1246:1-10.
29. Kyewski B., Derbinski J Self-representation in the thymus. an extended view. Nat Rev Immunol 2004, 4:688-698.
30. Chiovato L., Latrofa F., Braverman L.E, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003, 139:346-351.
31. Pisetsky D.S Fulfilling Koch's postulates of autoimmunity. anti-NR2 antibodies in mice and men. Arthritis Rheum 2006, 54:2349-2352.
32. Goodnow C.C, Sprent J., de St Groth B.F, Vinuesa C.G Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
33. Viret C., Sant'Angelo D.B, He X, et al. A role for accessibility to self-peptide-self-MHC complexes in intrathymic negative selection. J Immunol 2001, 166:4429-4437.
34. Vafiadis P., Ounissi-Benkalha H., Palumbo M, et al. Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type 1 diabetes 10.1210/jc.86.8.3705. J Clin Endocrinol Metab 2001, 86:3705-3710.
35. Cohen I.R Antigenic mimicry, clonal selection and autoimmunity. J Autoimmun 2001, 16:337-340.
36. Damico F.M, Kiss S., Young L.H Sympathetic ophthalmia. Semin Ophthalmol 2005, 20(197):191.
37. Chang G.C, Young L.H Sympathetic ophthalmia. Semin Ophthalmol 2011, 26:316-320.
38. Zhang M., Alicot E.M, Chiu I, et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006, 203:141-152.
39. Cusick M.F, Libbey J.E, Fujinami R.S Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 2012, 42:102-111.
40. Soulas P., Woods A., Jaulhac B, et al. Autoantigen, innate immunity, and T cells cooperate to break B cell tolerance during bacterial infection. J Clin Invest 2005, 115:2257-2267.
41. Olson J.K, Croxford J.L, Miller S.D Virus-induced autoimmunity. potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 2001, 14:227-250.
42. Ziegler A.G, Schmid S., Huber D, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003, 290:1721-1728.
43. McKay D.M Bacterial superantigens. provocateurs of gut dysfunction and inflammation. Trends Immunol 2001, 22:497-501.
44. Michels A.W, Gottlieb P.A Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010, 6:270-277.
45. Owen C.J, Cheetham T.D Diagnosis and management of polyendocrinopathy syndromes. Endocrinol Metab Clin North Am 2009, 38:419-436.
46. Tait K.F, Gough S.C.L The genetics of autoimmune endocrine disease. Clin Endocrinol 2003, 59:1-11.
47. Miyazaki Y., Hirayama M., Watanabe H, et al. Paraneoplastic encephalitis associated with myasthenia gravis and malignant thymoma. J Clin Neurosci 2012, 19:336-338.
48. Naoura I., Didelot A., Walker F, et al. Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas. a case report. Am J Obstet Gynecol 2011, 205:e6-e8.
49. Rosin L., DeCamilli P., Butler M, et al. Stiff-man syndrome in a woman with breast cancer. an uncommon central nervous system paraneoplastic syndrome. Neurology 1998, 50:94-98.
50. Husebye E.S, Perheentupa J., Rautemaa R., Kampe O Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009, 265:514-529.
51. Perheentupa J Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
52. Buzi F., Badolato R., Mazza C, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. time to review diagnostic criteria. J Clin Endocrinol Metab 2003, 88:3146-3148.
53. Peterson P., Peltonen L. Autoimmune polyendocrinopathy syndrome type 1 (APS1) and AIRE gene. New views on molecular basis of autoimmunity. J Autoimmun 2005, 25:49-55.
54. Schmidt M Eine biglandulare Erkrankung (Nebennieren und Schilddrusse) bei Morbus Addisonii. Verh Dtsch Ges Pathol Ges 1926, 21:212-221. (in German).
55. Carpenter C.C, Solomon N., Silverberg S.G, et al. Schmidt's syndrome (thyroid and adrenal insufficiency). a review of the literature and a report of fifteen new cases including ten instances of coexistent diabetes mellitus. Medicine (Baltimore) 1964, 43:153-180.
56. Eisenbarth G.S, Gottlieb P.A Autoimmune polyendocrine syndromes. N Engl J Med 2004, 350:2068-2079.
57. Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes. autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002, 23:327-364.
58. Amerio P., Tracanna M., De Remigis P., et al. Vitiligo associated with other autoimmune diseases. polyglandular autoimmune syndrome types 3B1C and 4. Clin Exp Dermatol 2006, 31:746-749.
59. Kumar G.P, Laloraya M., Wang C.Y, et al. The autoimmune regulator (AIRE) is a DNA-binding protein. J Biol Chem 2001, 276:41357-41364.
60. Wolff A.S, Erichsen M.M, Meager A., et al. Autoimmune polyendocrine syndrome type 1 in Norway. phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007, 92:595-603.
61. Rautemaa R., Hietanen J., Niissalo S., et al. Oral and oesophageal squamous cell carcinoma-a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol 2007, 43:607-613.
62. Siikala E., Richardson M., Pfaller M.A, et al. Candida albicans isolates from APECED patients show decreased susceptibility to miconazole. Int J Antimicrob Agents 2009, 34:607-609.
63. Rautemaa R., Richardson M., Pfaller M., et al. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008, 40:904-907.
64. Winer K.K, Sinaii N., Peterson D., et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 2008, 93:3389-3395.
65. Maclaren N., Chen Q.Y, Kukreja A., et al. Autoimmune hypogonadism as part of an autoimmune polyglandular syndrome. J Soc Gynecol Investig 2001, 8:S52-S54.
66. Soderbergh A., Myhre A.G, Ekwall O., et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004, 89:557-562.
67. Ahonen P., Myllarniemi S., Sipila I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990, 322:1829-1836.
68. Gazulla Abio J., Benavente Aguilar I., Ricoy Campo J.R, Madero Barrajon P Myopathy with trabecular fibers associated with familiar autoimmune polyglandular syndrome type 1. Neurologia 2005, 20:702-708.
69. De Luca F., Valenzise M., Alaggio R., et al. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. Eur J Pediatr 2008, 167:1283-1288.
70. Doniach D., Roitt I.M Auto-immunity in Hashimoto's disease and its implications. J Clin Endocrinol Metab 1957, 17:1293-1304.
71. Betterle C., Lazzarotto F., Presotto F. Autoimmune polyglandular syndrome type 2. the tip of an iceberg. Clin Exp Immunol 2004, 137:225-233.
72. Hugle B., Dollmann R., Keller E., Kiess W. Addison's crisis in adolescent patients with previously diagnosed diabetes mellitus as manifestation of polyglandular autoimmune syndrome type II-report of two patients. J Pediatr Endocrinol Metab 2004, 17:93-97.
73. Hollowell G, Staehling N.W, Flanders W.D, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994). National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87:489-499.
74. Jaeger C., Hatziagelaki E., Petzoldt R., Bretzel R.G Comparative analysis of organ-specific autoantibodies and celiac disease-associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects. Diabetes Care 2001, 24:27-32.
75. Kordonouri O., Klinghammer A., Lang E.B, et al. Thyroid autoimmunity in children and adolescents with type 1 diabetes. a multicenter survey. Diabetes Care 2002, 25:1346-1350.
76. Alkhateeb A., Fain P.R, Thody A., et al. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families pigment cell research. Pigment Cell Research 2003, 16:208-214.
77. Ruggeri R.M, Galletti M., Mandolfino M.G, et al. Thyroid hormone autoantibodies in primary Sjogren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases. J Endocrinol Invest 2002, 25:447-454.
78. Tsao C.Y, Mendell J.R, Lo W.D, et al. Myasthenia gravis and associated autoimmune diseases in children. J Child Neurol 2000, 15:767-769.
79. Zetting G., Tanew A., Fischer G., et al. Autoimmune diseases in vitiligo. do anti-nuclear antibodies decrease thyroid volume. Clin Exp Immunol 2003, 131:347-354.
80. Kakourou T., Kanaka-Gantenbein C., Papadopoulou A., et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005, 53:220-223.
81. Hann S.K, Lee H.J Segmental vitiligo. clinical findings in 208 patients. J Am Acad Dermatol 1996, 35:671-674.
82. Tanwani L.K, Lohano V., Ewart R., et al. Myasthenia gravis in conjunction with Graves' disease. a diagnostic challenge. Endocr Pract 2001, 7:275-278.
83. Weetman A.P Non-thyroid autoantibodies in autoimmune thyroid disease. Best Pract Res Clin Endocrinol Metab 2005, 19:17-32.
84. Weinstock C., Matheis N., Barkia S., et al. Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes. Tissue Antigens 2011, 77:317-324.
85. Karvonen M., Viik Kajander M., Moltchanova E., et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23:1516-1526.
86. Stenstrom G., Gottsater A., Bakhtadze E., et al. Latent autoimmune diabetes in adults. definition, prevalence, {beta}-cell function, and treatment. Diabetes 2005, 54:S68-S72.
87. Alonso N., Granada M.L, Salinas I., et al. An early marker of pernicious anemia in patients with type 1 diabetes 10.1210/jc.2005-0580. J Clin Endocrinol Metab 2005, 90:5254-5258.
88. Segni M., Borrelli O., Pucarelli I., et al. Early manifestations of gastric autoimmunity in patients with juvenile autoimmune thyroid diseases. J Clin Endocrinol Metab 2004, 89:4944-4948.
89. Barker J.M Type 1 diabetes-associated autoimmunity. natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006, 91:1210-1217.
90. Barker J.M, Ide A., Hostetler C., et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies. Addison's disease in a high-risk population. J Clin Endocrinol Metab 2005, 90:128-134.
91. Hansson T., Dahlbom I., Rogberg S., et al. Recombinant human tissue transglutaminase for diagnosis and follow-up of childhood coeliac disease. Pediatr Res 2002, 51:700-705.
92. Smith C.M, Clarke C.F, Porteous L.E, et al. Prevalence of coeliac disease and longitudinal follow-up of antigliadin antibody status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2000, 1:199-203.
93. Not T., Tommasini A., Tonini G., et al. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with type I diabetes mellitus. Diabetologia 2001, 44:151-155.
94. Welt C.K, Falorni A., Taylor A.E, et al. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. J Clin Endocrinol Metab 2005, 90:3069-3076.
95. Cemeroglu A.P, Bober E., Dundar B., Buyukgebiz A Autoimmune polyglandular endocrinopathy and anterior hypophysitis in a 14 year-old girl presenting with delayed puberty. J Pediatr Endocrinol Metab 2001, 14:909-914.
96. Zung A., Andrews-Murray G., Winqvist O., Chalew S.A Growth hormone deficiency in autoimmune polyglandular syndrome. J Pediatr Endocrinol Metab 1997, 10:69-72.
97. Govindarajan R., Galpin O.P Coexistence of Addison's disease, ulcerative colitis, hypothyroidism and pernicious anemia. J Clin Gastroenterol 1992, 15:82-83.
98. Ko G.T, Szeto C.C, Yeung V.T, et al. Autoimmune polyglandular syndrome and primary biliary cirrhosis. Br J Clin Pract 1996, 50:344-346.
99. Papadopoulos K.I, Hornblad Y., Liljebladh H., Hallengren B. High frequency of endocrine autoimmunity in patients with sarcoidosis. Eur J Endocrinol 1996, 134:331-336.
100. Watson J.P, Lewis R.A Schmidt's syndrome associated with sarcoidosis. Postgrad Med J 1996, 72:435-436.
101. Fritzen R., Bornstein S.R, Scherbaum W.A Megaoesophagus in a patient with autoimmune polyglandular syndrome type II. Clin Endocrinol (Oxf) 1996, 45:493-498.
102. Heuss D., Engelhardt A., Gobel H., Neundorfer B. Myopathological findings in interstitial myositis in type II polyendocrine autoimmune syndrome (Schmidt's syndrome). Neurol Res 1995, 17:233-237.
103. Watkins P.J, Gayle C., Alsanjari N., et al. Severe sensory-autonomic neuropathy and endocrinopathy in insulin-dependent diabetes. Qjm 1995, 88:795-804.
104. Wildin R.S, Freitas A. IPEX and FOXP3. Clinical and research perspectives. J Autoimmun 2005, 25:56-62.
105. Bennett C.L, Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
106. Wildin R.S, Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
107. Zavattari P., Deidda E., Pitzalis M., et al. No association between variation of the FOXP3 gene and common type 1 diabetes in the Sardinian population. Diabetes 2004, 53:1911-1914.
108. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
109. Hori S., Takahashi T., Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003, 81:331-371.
110. Meager A., Visvalingam K., Peterson P., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006, 3:e289.
111. Meloni A., Furcas M., Cetani F., et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008, 93:4389-4397.
112. Oftedal B.E, Wolff A.S, Bratland E., et al. Radioimmunoassay for autoantibodies against interferon omega ; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 2008, 129:163-169.
113. Zhang L., Barker J.M, Babu S., et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol 2007, 125:131-137.
114. Alimohammadi M., Bjorklund P., Hallgren A., et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008, 358:1018-1028.
115. Gavalas N.G, Kemp E.H, Krohn K.J, et al. The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2007, 92:2107-2114.
116. O'Dwyer D.T, McElduff P., Peterson P., et al. Pituitary autoantibodies in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Acta Biomed 2007, 78(Suppl. 1):248-254.
117. Puel A., Doffinger R., Natividad A., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
118. Bright G.M, Blizzard R.M, Kaiser D.L, Clarke W.L Organ-specific autoantibodies in children with common endocrine diseases. J Pediatr 1982, 100:8-14.
119. Elin R.J, Winter W.E Methylmalonic acid. a test whose time has come. Arch Pathol Lab Med 2001, 125:824-827.
120. Coco G., Dal Pra C., Presotto F., et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006, 91:1637-1645.
121. Betterle C., Coco G., Zanchetta R. Adrenal cortex autoantibodies in subjects with normal adrenal function. Best Pract Res Clin Endocrinol Metab 2005, 19:85-99.
122. Ahonen P. Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED). autosomal recessive inheritance. Clin Genet 1985, 27:535-542.
123. Aaltonen J., Bjorses P., Sandkuijl L., et al. An autosomal locus causing autoimmune disease. autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994, 8:83-87.
124. Trebusak Podkrajsek K., Bratanic N., Krzisnik C., Battelino T. Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. J Clin Endocrinol Metab 2005, 90:4930-4935.
125. Meloni A., Fiorillo E., Corda D., et al. Two novel mutations of the AIRE protein affecting its homodimerization properties. Hum Mutat 2005, 25:319.
126. Ulinski T., Perrin L., Morris M., et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure. impact of posttransplant immunosuppression on disease activity. J Clin Endocrinol Metab 2006, 91:192-195.
127. Cervato S., Mariniello B., Lazzarotto F., et al. Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf) 2009, 70:421-428.
128. F Magitta N., Pura M., S Bøe Wolff A., et al. Autoimmune polyendocrine syndrome type I in Slovakia. relevance of screening patients with autoimmune Addison's disease. Eur J Endocrinol 2008, 158:705-709.
129. Zuklys S., Balciunaite G., Agarwal A., et al. Normal thymic architecture and negative selection are associated with Aire Expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Immunol 2000, 165:1976-1983.
130. Wallaschofski H., Meyer A., Tuschy U., Lohmann T. HLA-DQA1*0301-associated susceptibility for autoimmune polyglandular syndrome type II and III. Horm Metab Res 2003, 35:120-124.
131. Robles D.T, Fain P.R, Gottlieb P.A, Eisenbarth G.S The genetics of autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin North Am 2002, 31:353-368. vi-vii.
132. Brewer K.W, Parziale V.S, Eisenbarth G.S Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 1997, 337:202.
133. Myhre A.G, Undlien D.E, Lovas K., et al. Autoimmune adrenocortical failure in norway autoantibodies and human leukocyte antigen class ii associations related to clinical features. J Clin Endocrinol Metab 2002, 87:618-623.
134. Hunt P.J, Marshall S.E, Weetman A.P, et al. Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clinical Endocrinology 2001, 55:491-499.
135. Levin L., Ban Y., Concepcion E., et al. Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Hum Immunol 2004, 65:640-647.
136. Vaidya B., Imrie H., Geatch D.R, et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. J Clin Endocrinol Metab 2000, 85:688-691.
137. Schott M., Minich W.B, Willenberg H.S, et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves disease. Horm Metab Res 2005, 37:741-744.
138. Winter W.E, Harris N., Schatz D Immunological markers in the diagnosis and prediction of autoimmune type 1a diabetes. Clin Diabetes 2002, 20:183-191.
139. Winter W.E, Harris N., Schatz D. Type 1 diabetes islet autoantibody markers. Diabetes Technol Ther 2002, 4:817-839.
140. Soderbergh A., Myhre A.G, Ekwall O., et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004, 89:557-562.
141. Ng W.F, von Delwig A., Carmichael A.J, et al. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol 2010, 126:1006-1015. e1001-e1004.
142. Browne S.K, Holland S.M Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 2010, 10:534-541.
143. Blizzard R.M, Kyle M. Studies of the adrenal antigens and antibodies in Addison's disease. J Clin Invest 1963, 42:1653-1660.
144. Drexhage H.A, Bottazzo G.F, Bitensky L., et al. Thyroid growth-blocking antibodies in primary myxoedema. Nature 1981, 289:594-596.
145. Betterle C., Volpato M., Pedini B., et al. Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease. comparison of immunofluorescence and immunoprecipitation assays. J Clin Endocrinol Metab 1999, 84:618-622.
146. Betterle C., Volpato M., Smith B.R, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases. markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 1997, 82:932-938.
147. Khoury E.L, Hammond L., Bottazzo G.F, Doniach D. Surface-reactive antibodies to human adrenal cells in Addison's disease. Clin Exp Immunol 1981, 45:48-55.
148. Husebye E.S, Bratland E., Bredholt G., et al. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology 2006, 147:2411-2416.
149. de Carmo Silva R., Kater C., Dib S.A, et al. Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III. Eur J Endocrinol 2000, 142:187-194.
150. Nikoshkov A., Falorni A., Lajic S., et al. A conformation-dependent epitope in Addison's disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. J Immunol 1999, 162:2422-2426.
151. Peterson P., Krohn K.J Mapping of B cell epitopes on steroid 17 alpha-hydroxylase, an autoantigen in autoimmune polyglandular syndrome type I. Clin Exp Immunol 1994, 98:104-109.
152. Liiv I., Teesalu K., Peterson P., et al. Epitope mapping of cytochrome P450 cholesterol side-chain cleavage enzyme by sera from patients with autoimmune polyglandular syndrome type 1. Eur J Endocrinol 2002, 146:113-119.
153. Ross I., Boulle A., Soule S., et al. Autoimmunity predominates in a large South African cohort with Addison's disease of mainly European descent despite long-standing disease and is associated with HLA DQB*0201. Clin Endocrinol (Oxf) 2010, 73:291-298.
154. Falorni A., Laureti S., Santeusanio F. Autoantibodies in autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin North Am 2002, 31:369-389. vii.
155. Betterle C., Lazzarotto F., Presotto F. Autoimmune polyglandular syndrome type 2. the tip of an iceberg. Clin Exp Immunol 2004, 137:225-233.
156. Nikoshkov A., Falorni A., Lajic S., et al. A conformation-dependent epitope in Addison's disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. J Immunol 1999, 162:2422-2426.
157. Dal Pra C., Chen S., Furmaniak J., et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison's disease. Eur J Endocrinol 2003, 148:565-570.
158. Goswami D., Conway G.S Premature ovarian failure. Hum Reprod Update 2005, 11:391-410.
159. Bakalov V.K, Vanderhoof V.H, Bondy C.A, Nelson L.M Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002, 17:2096-2100.
160. Santoro N. Research on the mechanisms of premature ovarian failure. J Soc Gynecol Investig 2001, 8:S10-S12.
161. Irvine W.J, Chan M.M, Scarth L., et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison's disease. Lancet 1968, 2:883-887.
162. Ahonen P., Miettinen A., Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987, 64:494-500.
163. Falorni A., Laureti S., Candeloro P., et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002, 78:270-279.
164. Reimand K., Peterson P., Hyoty H., et al. 3{beta}-Hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure. J Clin Endocrinol Metab 2000, 85:2324-2326.
165. Shivers C.A, Dunbar B.S Autoantibodies to zona pellucida. a possible cause for infertility in women. Science 1977, 197:1082-1084.
166. Uibo R., Aavik E., Peterson P., et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 1994, 78:323-328.
167. Soderbergh A., Rorsman F., Halonen M., et al. Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease. J Clin Endocrinol Metab 2000, 85:460-463.
168. Blizzard R.M, Chee D., Davis W. The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol 1966, 1:119-128.
169. Irvine W.J, Scarth L. Antibody to the oxyphil cells of the human parathyroid in idiopathic hypoparathyroidism. Clin Exp Immunol 1969, 4:505-510.
170. Chapman C.K, Bradwell A.R, Dykks P.W Do parathyroid and adrenal autoantibodies coexist. J Clin Pathol 1986, 39:813-814.
171. Betterle C., Caretto A., Zeviani M., et al. Demonstration and characterization of anti-human mitochondria autoantibodies in idiopathic hypoparathyroidism and in other conditions. Clin Exp Immunol 1985, 62:353-360.
172. Brandi M.L, Aurbach G.D, Fattorossi A., et al. Antibodies cytotoxic to bovine parathyroid cells in autoimmune hypoparathyroidism. Proc Natl Acad Sci USA 1986, 83:8366-8369.
173. Fattorossi A., Aurbach G.D, Sakaguchi K., et al. Anti-endothelial cell antibodies. detection and characterization in sera from patients with autoimmune hypoparathyroidism. Proc Natl Acad Sci USA 1988, 85:4015-4019.
174. McElduff A., Lackmann M., Wilkinson M. Antiidiotypic PTH antibodies as a cause of elevated immunoreactive parathyroid hormone in idiopathic hypoparathyroidism, a second case. another manifestation of autoimmune endocrine disease. Calcif Tissue Int 1992, 51:121-126.
175. Kifor O., McElduff A., LeBoff M.S, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004, 89:548-556.
176. Kifor O., Moore F.D, Delaney M., et al. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 2003, 88:60-72.
177. Tomar N., Kaushal E., Das M., et al. Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J Clin Endocrinol Metab 2012, 97:1219-1226.
178. Hedstrand H., Ekwall O., Haavik J., et al. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochem Biophys Res Commun 2000, 267:456-461.
179. Diamantis I., Boumpas D.T Autoimmune hepatitis. evolving concepts. Autoimmun Rev 2004, 3:207-214.
180. Ekwall O., Hedstrand H., Haavik J., et al. Pteridin-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2000, 85:2944-2950.